Can a diabetes drug help dialysis patients? small study aims to find out

NCT ID NCT05687058

Ongoing Knowledge-focused Sponsor: University of Mississippi Medical Center Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early study is testing whether the diabetes and heart failure drug empagliflozin (Jardiance) is safe for people on dialysis for kidney failure. The drug is already approved for other uses but has not been studied in dialysis patients. Researchers will give 24 participants either a thrice-weekly or daily dose for three months, monitoring safety and how well they tolerate it. The goal is to gather information needed for a larger future trial.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Empagliflozin (Jardiance)
What this could lead to: If this study shows the drug is safe, it could pave the way for a larger trial testing whether empagliflozin protects the heart and remaining kidney function in dialysis patients.
What could go wrong: This is a very small, early feasibility study with only 24 participants. It is not designed to prove the drug works, and the drug has not been approved for dialysis patients. Safety risks are unknown.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for END STAGE KIDNEY DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic kidney disease chronic renal failure syndrome end stage renal failure heart failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEART FAILURE KIDNEY FAILURE, CHRONIC

Contacts and locations

Locations

Jackson Medicall Mall Dialysis Clinic

Jackson, Mississippi, 39213, United States
University of Mississippi Medical Center

Jackson, Mississippi, 39157, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.